ZLAB - Zai Lab's repotrectinib for lung cancer subtype gets breakthrough therapy tag in China

Zai Lab (NASDAQ:ZLAB) said the Center for Drug Evaluation of China's National Medical Products Administration granted breakthrough therapy designation to repotrectinib for treating patients with ROS1-positive metastatic non-small-cell lung cancer (NSCLC) who have not been treated with a ROS1 tyrosine kinase inhibitor (TKI). The designation was backed by initial data from both global and Chinese TKI-naïve ROS1-positive NSCLC patients enrolled in a phase 1/2 TRIDENT-1 study.

For further details see:

Zai Lab's repotrectinib for lung cancer subtype gets breakthrough therapy tag in China